Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 EPS of ($0.38), $0.09 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $4.8 million.

Cash and Financial Guidance:

Cash, cash equivalents and marketable securities as of December 31, 2021 were $143.4 million, as compared with $174.0 million on December 31, 2020. This change reflects cash used to fund Syros’ operations during the full year ended December 31, 2021, partially offset by gross proceeds of $75.6 million that Syros received from its January 2021 public offering.

Based on its current plans, Syros believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its planned operating expenses and capital expenditure requirements into the first quarter of 2023.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.